Melanoma Drugs Market Report 2026

The melanoma drugs market size has grown rapidly in recent years. It will grow from $10.15 billion in 2025 to $11.21 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to growing incidence of melanoma, increasing awareness about skin cancer, approval of early immunotherapy drugs, rising adoption of targeted therapies, expansion of hospital oncology departments.

The melanoma drugs market size is expected to see rapid growth in the next few years. It will grow to $17.07 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to advances in precision medicine, development of combination therapies, rising geriatric population, increased funding for melanoma research, integration of ai in drug discovery. Major trends in the forecast period include personalized melanoma therapy development, targeted immunotherapy advancements, combination treatment approaches, early detection and diagnostic innovations, orphan and rare melanoma treatment focus.

The increasing incidence of melanoma among males is expected to drive the growth of the melanoma drug market in the coming years. Melanoma is a form of skin cancer that develops in melanocytes, the cells responsible for skin pigmentation. Melanoma drugs are therapeutic agents used to treat this condition by targeting and inhibiting the growth and spread of melanoma cells within the body. As the number of melanoma cases continues to rise, the demand for effective melanoma treatments is also increasing. For instance, in 2023, according to a report published by the American Cancer Society, the number of newly diagnosed male melanoma cases in the United States rose to 58,120 in 2023, up from 57,180 in 2022. Therefore, the growing incidence of melanoma in males is contributing to the expansion of the melanoma drug market.

Companies operating in the melanoma drug market are increasingly concentrating on the development of next-generation cell-based immunotherapies, such as tumor-infiltrating lymphocyte (TIL) therapies, to improve treatment effectiveness for patients with advanced or unresectable melanoma. TIL therapy involves isolating a patient’s own tumor-infiltrating immune cells, expanding them outside the body, and reinfusing them to enhance the immune system’s ability to identify and destroy cancer cells. This approach offers a promising option for patients who have shown limited response to existing systemic immunotherapies. For example, in February 2024, Iovance Biotherapeutics received approval from the U.S. Food and Drug Administration for AMTAGVI (lifileucel), the first tumor-infiltrating lymphocyte therapy approved for advanced melanoma. According to the FDA, AMTAGVI demonstrated an overall response rate of 31.5%, including 5.6% complete responses, in heavily pretreated patients with unresectable or metastatic melanoma. As a personalized, one-time cellular immunotherapy, AMTAGVI represents a major therapeutic advancement and expands available options for patients with limited treatment alternatives.

In May 2025, Sun Pharmaceutical Industries Limited, an India-based provider of specialty generics, dermatology products, and onco-dermatology therapies, acquired Checkpoint Therapeutics for an undisclosed amount. Through this acquisition, Sun Pharma aims to strengthen its immuno-oncology portfolio by adding a first-in-class anti-PD-L1 therapy and expanding its capabilities in advanced skin cancer treatment. Checkpoint Therapeutics is a US-based developer of novel immunotherapies and targeted oncology medicines focused on skin cancers and other solid tumors.

Major companies operating in the melanoma drugs market are Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., Merck & Co. Inc., Aduro Biotech Inc., Seagen Inc., OncoSec Medical Incorporated, Regeneron Pharmaceuticals Inc., Iovance Biotherapeutics, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Daiichi Sankyo Company Limited, Gilead Sciences, MacroGenics Inc., Kyowa Kirin Co. Ltd., Fortress Biotech Inc., OSE Immunotherapeutics, Vical Incorporated, Almirall S.A.

North America was the largest region in the melanoma drugs market in 2025. The regions covered in the melanoma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the melanoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the melanoma drugs market by increasing costs of imported active pharmaceutical ingredients (APIs) and laboratory equipment, thereby impacting production and R&D efficiency. The segments most affected include chemotherapy and targeted therapy drug production, particularly in regions like north america and europe that rely on imports from asia-pacific. While tariffs have posed cost challenges, they have also encouraged local manufacturing and investment in domestic production capacities, fostering innovation and resilience in the melanoma treatment supply chain.

The melanoma drugs market research report is one of a series of new reports that provides melanoma drugs market statistics, including melanoma drugs industry global market size, regional shares, competitors with a melanoma drugs market share, detailed melanoma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the melanoma drugs industry. This melanoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Melanoma drugs are medications used in the treatment of skin cancer that originates in melanocytes, the cells responsible for producing melanin, which gives color to the skin, hair, and eyes. These drugs are designed to treat melanoma by targeting and inhibiting the growth and spread of melanoma cells throughout the body.

The main therapeutic approaches for melanoma drugs include chemotherapy, immunotherapy, and targeted therapy. Chemotherapy is a treatment method that uses drugs to destroy or slow the growth of cancer cells and is often used alongside other treatments such as surgery and radiation therapy. Melanoma drugs are used to treat superficial spreading melanoma, lentigo maligna melanoma, acral lentiginous melanoma, and nodular melanoma, and are administered in hospitals, outpatient oncology clinics, and other healthcare settings.

The melanoma drug market consists of sales of pembrolizumab, nivolumab, vemurafenib, avelumab, and dabrafenib with trametinib drugs used for the treatment of melanoma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.